SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

RBC Says Edgewise Investors Focus on '7500 Phase 3 Design

RBC says investors are focused on the upcoming Phase 3 design for Edgewise Therapeutics' '7500 in hypertrophic cardiomyopathy.

EWTX

Related stories